Kolexia
Loulergue Pierre Maladies infectieuses
Loulergue Pierre
Maladies infectieuses
Hôpital Cochin
Paris, France
138 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Grippe humaine Infections à VIH Dysenterie bacillaire Neutropénie Rougeole Paludisme Paludisme à Plasmodium falciparum Hépatite Coqueluche

Collaborateurs

Voir plus
Launay Odile
Launay Odile
Hôpital Cochin, Paris, France
Mir Olivier
Mir Olivier
Amgen Sas, Neuilly-sur-Seine, France
Duval Xavier
Duval Xavier
Hôpital Bichat-Claude-Bernard, Paris, France
Galtier Florence
Galtier Florence
Hôpital Saint-Éloi, Montpellier, France

Industries

Voir plus
B3TSI
51 collaboration(s)
Dernière en 2023
Ipsos Mori UK Limited
21 collaboration(s)
Dernière en 2021
TBWA\ADELPHI
5 collaboration(s)
Dernière en 2021
Inter-View Partners France
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses: Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Fluad Seasonal Influenza Vaccine or Placebo in Healthy Adults
Essai Clinique (University Hospital, Ghent)   19 décembre 2022
Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.
Annals of oncology : official journal of the European Society for Medical Oncology   26 mars 2020
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
The Lancet. Infectious diseases   04 février 2020
PRIMALVAC: Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE
Essai Clinique (Institut National de la Santé Et de la Recherche Médicale, France)   27 novembre 2019
Trends in seasonal influenza vaccine coverage of target groups in France, 2006/07 to 2015/16: Impact of recommendations and 2009 influenza A(H1N1) pandemic.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin   11 octobre 2019
Trajectories of seasonal influenza vaccine uptake among French people with diabetes: a nationwide retrospective cohort study, 2006-2015.
BMC public health   09 juillet 2019
A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study: A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study
Essai Clinique (GSK)   13 juin 2019
Vaccine against chickenpox: where are we now?.
La Revue du praticien   16 mai 2019
Booster Vaccination With GVGH 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial.
Frontiers in immunology   08 mars 2019
Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination.
The Journal of clinical investigation   07 mars 2019